Tessa Romero
Stock Analyst at JP Morgan
(4.42)
# 357
Out of 5,182 analysts
83
Total ratings
54.69%
Success rate
21.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Neutral | $31 → $36 | $24.43 | +47.36% | 9 | Apr 6, 2026 | |
| SEPN Septerna | Maintains: Overweight | $34 → $38 | $25.07 | +51.61% | 1 | Mar 24, 2026 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $34 → $45 | $30.64 | +46.87% | 12 | Mar 17, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $74 → $75 | $61.60 | +21.75% | 7 | Mar 17, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $47 → $50 | $46.29 | +8.01% | 7 | Mar 16, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $31 → $34 | $22.30 | +52.47% | 12 | Mar 4, 2026 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $17 → $16 | $18.04 | -11.31% | 8 | Jan 20, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $60 → $62 | $54.26 | +14.26% | 4 | Jan 9, 2026 | |
| OCS Oculis Holding AG | Initiates: Overweight | $38 | $27.11 | +40.17% | 1 | Dec 19, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $47 → $15 | $9.59 | +56.41% | 8 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $261 → $263 | $3.49 | +7,435.82% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.22 | - | 5 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $10 | $5.63 | +77.78% | 2 | May 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $9.29 | +309.04% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $7.32 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $29 | $13.60 | +113.24% | 3 | Aug 13, 2024 |
Agios Pharmaceuticals
Apr 6, 2026
Maintains: Neutral
Price Target: $31 → $36
Current: $24.43
Upside: +47.36%
Septerna
Mar 24, 2026
Maintains: Overweight
Price Target: $34 → $38
Current: $25.07
Upside: +51.61%
Edgewise Therapeutics
Mar 17, 2026
Maintains: Overweight
Price Target: $34 → $45
Current: $30.64
Upside: +46.87%
Cytokinetics
Mar 17, 2026
Maintains: Overweight
Price Target: $74 → $75
Current: $61.60
Upside: +21.75%
Scholar Rock Holding
Mar 16, 2026
Maintains: Overweight
Price Target: $47 → $50
Current: $46.29
Upside: +8.01%
ACADIA Pharmaceuticals
Mar 4, 2026
Maintains: Overweight
Price Target: $31 → $34
Current: $22.30
Upside: +52.47%
Dyne Therapeutics
Jan 20, 2026
Maintains: Neutral
Price Target: $17 → $16
Current: $18.04
Upside: -11.31%
Xenon Pharmaceuticals
Jan 9, 2026
Maintains: Overweight
Price Target: $60 → $62
Current: $54.26
Upside: +14.26%
Oculis Holding AG
Dec 19, 2025
Initiates: Overweight
Price Target: $38
Current: $27.11
Upside: +40.17%
Biohaven
Nov 20, 2025
Maintains: Overweight
Price Target: $47 → $15
Current: $9.59
Upside: +56.41%
Nov 18, 2025
Downgrades: Underweight
Price Target: $261 → $263
Current: $3.49
Upside: +7,435.82%
Sep 16, 2025
Downgrades: Underweight
Price Target: n/a
Current: $2.22
Upside: -
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $5.63
Upside: +77.78%
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $9.29
Upside: +309.04%
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $7.32
Upside: -
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $13.60
Upside: +113.24%